Literature DB >> 2242327

The pathophysiology of Sandimmune (cyclosporine) in man and animals.

J Mason1.   

Abstract

Part I: The side-effects of Sandimmune that have been of most significance clinically are renal dysfunction, renal vascular damage and arterial hypertension. To examine the nature and the origin of such effects, the actions of Sandimmune on the renal tubule, the renal vessels and systemic vessels have been analyzed. To evaluate whether common vasoconstrictory systems may be involved, changes in the renin-angiotensin-aldosterone system and prostaglandin-thromboxane system have been assessed. Comparison between animal and human data obtained in vivo and in vitro shows the actions of Sandimmune on the renal tubule to be modest and involve only a few specific effects. The major action of Sandimmune is on the vessels, vasoconstriction being the major cause of renal dysfunction and also the cause of arterial hypertension. Neither the circulating renin-angiotension-aldosterone system nor the prostaglandin-thromboxane system is clearly responsible for vasoconstriction. Although not itself a vasoconstrictor, Sandimmune seems to modulate the constrictory and dilatory response to other agents in several vascular beds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242327     DOI: 10.1007/bf00869843

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  194 in total

1.  What is cyclosporine nephrotoxicity?

Authors:  B D Myers
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Cyclosporine impairs the renal response to volume depletion.

Authors:  D A Laskow; J Curtis; R Luke; P Jones; H Barber; M Deierhoi; A Diethelm
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

3.  Effects of cyclosporine on renal hemodynamics and autoregulation in rats.

Authors:  F J Kaskel; P Devarajan; L A Arbeit; L C Moore
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

4.  The role of eicosanoids in cyclosporine nephrotoxicity in the rat.

Authors:  A Erman; B Chen-Gal; J Rosenfeld
Journal:  Biochem Pharmacol       Date:  1989-07-01       Impact factor: 5.858

5.  Effect of short-term cyclosporine A administration on urinary acidification.

Authors:  D C Batlle; C Gutterman; J Tarka; R Prasad
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

6.  Cyclosporin A and renal prostaglandin biosynthesis.

Authors:  C R Baxter; G G Duggin; J S Horvath; B M Hall; D J Tiller
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1984-07

7.  Side effects of cyclosporin A treatment in patients with rheumatoid arthritis.

Authors:  K J Berg; O Førre; F Bjerkhoel; E Amundsen; O Djøseland; H E Rugstad; B Westre
Journal:  Kidney Int       Date:  1986-06       Impact factor: 10.612

8.  Suppression of plasma renin activity by cyclosporine.

Authors:  J P Bantle; R J Boudreau; T F Ferris
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

9.  Renal function and blood pressure in patients treated with cyclosporin A for uveitis.

Authors:  G Deray; P Le Hoang; P Cacoub; B Aupetit; A Mertani; F Martinez; J Rottembourg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Cyclosporin A-induced increases in renin storage and release.

Authors:  C R Baxter; G G Duggin; N S Willis; B M Hall; J S Horvath; D J Tiller
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1982-08
View more
  12 in total

Review 1.  Chronic rejection and late renal allograft dysfunction.

Authors:  J Laine; C Holmberg; P Häyry
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

2.  Evaluating the effect of sulphated polysaccharides on cyclosporine a induced oxidative renal injury.

Authors:  Anthony Josephine; Coothan Kandaswamy Veena; Ganapathy Amudha; Sreenivasan P Preetha; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2006-05-16       Impact factor: 3.396

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; S Drechsler; H J Kramer
Journal:  Clin Investig       Date:  1993-02

5.  Urodilatin: a new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients.

Authors:  M Hummel; M Kuhn; A Bub; H Bittner; D Kleefeld; P Marxen; B Schneider; R Hetzer; W G Forssmann
Journal:  Clin Investig       Date:  1992-08

6.  Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome.

Authors:  S A Hulton; L Jadresic; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

Review 7.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

8.  Cyclosporin A does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat.

Authors:  L Klein; M S Lemel; M S Wolfe; J Shaffer
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

9.  [Kidney function of patients with healthy kidneys during cyclosporin treatment].

Authors:  P Heering; B Kutkuhn; G Kreuzpaintner; T Reinhard; R Sundmacher; B Grabensee
Journal:  Klin Wochenschr       Date:  1991-11-26

10.  HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension.

Authors:  Monika Niehof; Jürgen Borlak
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.